“First experience with jenavalve™: A single-centre cohort”

Abstract

Aims Since the introduction of transcatheter aortic valve implantation (TAVI), newer generation and novel devices such as the retrievable JenaValve™ have been developed. We evaluated the procedural and 6-month results of our first experience with implantation of the JenaValve™. Methods and results From June 2012 to December 2013, 24 consecutive patients (mean age 80±7 years, 42% male) underwent an elective transapical TAVI with the JenaValve™. Device success was 88%. The mortality rate was 4% at 30 days and 31% at 6 months. TAVI reduced the mean transvalvular gradient (44.2±11.1 mmHg vs. 12.3± 4.3 mmHg, p<0.001) and increased the mean aortic valve area (0.8 3±0.23 to 1.70±0.44 cm2). A mild paravalvular leakage (PVL) occurred in 4 patients (18%) and a moderate PVL in 1 patient (4%). Mean New York Heart Association Functional Class improved from 2.9±0.5 to 2.0±0.8 at 30 days. Conclusion TAVI using the JenaValve™ prosthesis seems adequate and safe in this first experience cohort.